Literature DB >> 8821060

The TaClo concept: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo), a new toxin for dopaminergic neurons.

G Bringmann1, R God, D Feineis, W Wesemann, P Riederer, W D Rausch, H Reichmann, K H Sontag.   

Abstract

Due to its structural analogy to the neurotoxin MPTP, "TaClo" (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline), a compound readily originating in vitro from tryptamine ("Ta") and chloral ("Clo"), is discussed as a potential natural inducer of parkinsonian-like symptoms. Its spontaneous formation in man has to be taken into account after application of the drug chloral hydrate or after exposure to the solvent trichloroethylene. This first representative of chloral-derived heterocycles could now indeed be demonstrated to be formed in vivo after application of its putative precursors to rats. In vivo analysis of the nigrostriatal dopamine metabolism, behavioural studies, and histochemical findings as well as a strong inhibition of the complex I of the mitochondrial respiratory chain revealed the neurotoxic potential of TaClo on the dopaminergic system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8821060

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  13 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

2.  Solvent exposures and Parkinson disease risk in twins.

Authors:  Samuel M Goldman; Patricia J Quinlan; G Webster Ross; Connie Marras; Cheryl Meng; Grace S Bhudhikanok; Kathleen Comyns; Monica Korell; Anabel R Chade; Meike Kasten; Benjamin Priestley; Kelvin L Chou; Hubert H Fernandez; Franca Cambi; J William Langston; Caroline M Tanner
Journal:  Ann Neurol       Date:  2011-11-14       Impact factor: 10.422

Review 3.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Trichloroethylene and Parkinson's Disease: Risk Assessment.

Authors:  Mei Liu; Eun-Joo Shin; Duy-Khanh Dang; Chun-Hui Jin; Phil Ho Lee; Ji Hoon Jeong; Seok-Joo Park; Yong-Sun Kim; Bin Xing; Tao Xin; Guoying Bing; Hyoung-Chun Kim
Journal:  Mol Neurobiol       Date:  2017-12-22       Impact factor: 5.590

5.  Traumatic brain injury and trichloroethylene exposure interact and produce functional, histological, and mitochondrial deficits.

Authors:  Andrew Sauerbeck; Randy Hunter; Guoying Bing; Patrick G Sullivan
Journal:  Exp Neurol       Date:  2011-12-20       Impact factor: 5.330

6.  Trichloroethylene, a ubiquitous environmental contaminant in the risk for Parkinson's disease.

Authors:  Briana R De Miranda; J Timothy Greenamyre
Journal:  Environ Sci Process Impacts       Date:  2020-01-30       Impact factor: 4.238

7.  Effect of 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo) on human serotonergic cells.

Authors:  G Bringmann; R Brückner; R Mössner; D Feineis; A Heils; K P Lesch
Journal:  Neurochem Res       Date:  2000-06       Impact factor: 3.996

8.  1-Trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo) Alters Cell Cycle Progression in Human Neuroblastoma Cell Lines.

Authors:  Rakesh Kumar Sharma; Eduardo Candelario-Jalil; Doris Feineis; Gerhard Bringmann; Bernd L Fiebich; Ravi Shankar Akundi
Journal:  Neurotox Res       Date:  2017-07-18       Impact factor: 3.911

Review 9.  Solvents and Parkinson disease: a systematic review of toxicological and epidemiological evidence.

Authors:  Edward A Lock; Jing Zhang; Harvey Checkoway
Journal:  Toxicol Appl Pharmacol       Date:  2012-12-07       Impact factor: 4.219

10.  Trichloroethylene induces dopaminergic neurodegeneration in Fisher 344 rats.

Authors:  Mei Liu; Dong-Young Choi; Randy L Hunter; Jignesh D Pandya; Wayne A Cass; Patrick G Sullivan; Hyoung-Chun Kim; Don M Gash; Guoying Bing
Journal:  J Neurochem       Date:  2009-11-17       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.